Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0001 0.00 (0.00%)
As of 07/9/2026 03:55 PM Eastern
Compare

SMFL vs. ADTX, CMRA, EFTR, SYRS, and CALA

Should you buy Smart for Life stock or one of its competitors? MarketBeat compares Smart for Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smart for Life include Aditxt (ADTX), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Syros Pharmaceuticals (SYRS), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Aditxt?

Smart for Life (NASDAQ:SMFL) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Smart for Life has a beta of 15.05, indicating that its stock price is 1,405% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Aditxt Neutral

Smart for Life has higher revenue and earnings than Aditxt. Smart for Life is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Aditxt$14.34K0.23-$41.71M-$100.79 thousandN/A

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Summary

Smart for Life beats Aditxt on 9 of the 12 factors compared between the two stocks.

How does Smart for Life compare to Comera Life Sciences?

Smart for Life (NASDAQ:SMFL) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Comera Life Sciences has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Smart for Life has a beta of 15.05, meaning that its share price is 1,405% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Comera Life Sciences N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Comera Life Sciences Neutral

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to eFFECTOR Therapeutics?

Smart for Life (NASDAQ:SMFL) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
eFFECTOR Therapeutics Neutral

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Smart for Life has a beta of 15.05, indicating that its share price is 1,405% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Syros Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Smart for Life has a beta of 15.05, meaning that its stock price is 1,405% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Syros Pharmaceuticals Neutral

Smart for Life's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Smart for Life has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Summary

Smart for Life beats Syros Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Calithera Biosciences?

Smart for Life (NASDAQ:SMFL) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Calithera Biosciences Neutral

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Smart for Life has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Smart for Life has a beta of 15.05, suggesting that its stock price is 1,405% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, suggesting that its stock price is 236% less volatile than the broader market.

Summary

Smart for Life beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$4.15B$6.82B$12.61B
Dividend YieldN/AN/A2.68%7.79%
P/E Ratio0.0010.3327.2724.57
Price / Sales0.002.20546.83110.45
Price / CashN/A7.1148.4559.17
Price / Book0.002.1310.906.39
Net Income-$22.68M$19.77M$3.57B$331.53M
7 Day PerformanceN/A0.72%-0.25%0.37%
1 Month PerformanceN/A2.58%5.77%2.17%
1 Year PerformanceN/A5.38%28.14%20.90%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-99.1%$1K$11.11MN/A110
ADTX
Aditxt
0.6586 of 5 stars		$0.01
flat		N/A-100.0%$4K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$3KN/AN/A10
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-96.3%$3K$386KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 7/10/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
This remarkable new power source will ignite America's next energy revolution
A 328-year supply of a clean, abundant energy resource was just confirmed beneath New England - the largest de...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Tech forecaster George Gilder - who identified Amazon when it was still just an online bookstore and predicted...
Eagle Publishing | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel